| ALGS Stock | | | USD 25.51 2.52 10.96% |
VP
TseI Lin is VP Head of Aligos Therapeutics
| Address | One Corporate Drive, South San Francisco, CA, United States, 94080 |
| Phone | 800 466 6059 |
| Web | https://www.aligos.com |
Aligos Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.6732) % which means that it has lost $0.6732 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.4669) %, meaning that it created substantial loss on money invested by shareholders. Aligos Therapeutics' management efficiency ratios could be used to measure how well Aligos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.61 in 2024.
Return On Capital Employed is likely to drop to -0.73 in 2024. At this time, Aligos Therapeutics'
Total Assets are comparatively stable compared to the past year.
Non Current Assets Total is likely to gain to about 14.9
M in 2024, despite the fact that
Other Assets are likely to grow to (2.3
M).
Aligos Therapeutics currently holds 11.14
M in liabilities with Debt to Equity
(D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Aligos Therapeutics has a current ratio of 5.19, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Aligos Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | VP Age |
| Leah JD | Inhibrx | N/A |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Aligos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. Aligos Therapeutics (ALGS) is traded on NASDAQ Exchange in USA. It is located in One Corporate Drive, South San Francisco, CA, United States, 94080 and employs 68 people. Aligos Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Aligos Therapeutics Leadership Team
Elected by the shareholders, the Aligos Therapeutics' board of directors comprises two types of representatives: Aligos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aligos. The board's role is to monitor Aligos Therapeutics' management team and ensure that shareholders' interests are well served. Aligos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aligos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leonid Beigelman, Pres Director | |
| Dr DABT, Executive Sciences | |
| Dr MBA, President CEO | |
| Kristina Engeseth, Ex Culture | |
| Lucinda JD, Chief VP | |
| John Fry, Ex Devel | |
| TseI Lin, VP Head | |
| Lesley CPA, Executive CFO | |
| Hardean MD, Chief Officer | |
| Julian DPHIL, Executive Officer | |
| Matthew MD, Executive Officer | |
| David Smith, Executive Operations | |
Aligos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aligos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to
measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.